Wedbush has an outperform rating on Apple's stock heading into the holiday season and a 12-month price target of $300, that's about 28% above its current price. It's the highest price target among the ...

Gerber has grown skeptical of Musk's other ventures in recent years, and has said previously that his side projects are ...

For some, Black Friday kicks off the holiday shopping season, a period of time that Apple (NASDAQ:AAPL) is heavily dependent ...

Tesla Inc.'s stock rose 1.8% Friday, after Wedbush analyst Dan Ives' published his latest bullish note on the EV maker, predicting that the artificial intelligence and autonomous driving opportunity ...

Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Gary Black of The Future Fund LLC confirmed that Tesla's Cybercab won't launch until 2026, dismissing early rollout rumors, ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

Technology giant Microsoft is the center of a major regulatory issue, the outcome of which is likely to impact the company's ...

Microsoft stock was lagging its tech peers on Friday as investors reacted to news the company is facing a broad inquiry from ...

Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...